Author(s)

Jie Li^*, RuiChen Hu, Mo Liang

Affiliation(s)

Department of Respiratory Medicine, Hunan Provincial People’s Hospital/The first affiliated hospital of Hunan Normal University, Changsha 410016, China.

Corresponding Author

Jie Li

ABSTRACT

Objective To systematically evaluate the meta-analysis of statins in the treatment of chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension (PH). Methods: Systematically searching PubMed,CBM, VIP and Wanfang databases, and comprehensively collecting randomized controlled trials (RCT) of statins in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. According to the inclusion and exclusion criteria, literatures were screened, Meta were extracted and methodological quality was evaluated, and meta-analysis was performed by RevMan 5. 0 software. Results: Seven RCTs were included, with a total of 356 patients. Including 2 placebo-controlled trials and 5 non-placebo-controlled trials. Meta-analysis showed that: ① statin could improve the mean pulmonary arterial pressure (mPAP) [MD=-3. 83 mmHg, 95% ,CI(-5. 2, -2. 43)}, and the pulmonary arterial systolic pressure (PASP) [MD =-5. 66 mmhg, 95%, cl (-7 ... ②statin can significantly reduce the endothelin -1( ET-1) value [MD =-3. 51 pg/m1, 95% Cl, (-4. 77,-2. 55)] and increase the nitric oxide (NO) value [SMD = 1. 06,95%, CI (0 .. ③statin can improve the percentage of forced expiratory volume in the first second (FEV,%) [MD = 2. 92,95%, CI (-2.83,8.68)]. Conclusion: Statins can significantly improve pulmonary artery pressure, pulmonary function and clinical efficacy in COPD patients with PH.

KEYWORDS

Chronic obstructive pulmonary disease; Statins; Meta analysis

CITE THIS PAPER

Jie Li, RuiChen Hu, Mo Liang. Meta-analysis of statins in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. Journal of Pharmaceutical and Medical Research. 2024, 6(2): 41-53. DOI: 10.61784/jpmr3002.

REFERENCES

[1]Jiang Jiajia, Feng Jing, Dai Rong, et al. Meta-analysis of therapeutic effect of statins on chronic obstructive pulmonary disease complicated with pulmonary hypertension. Medical Herald, 2017.

[2]Yu Fengxia, Li Yuanyuan, Yu Shuhui, Hook. Meta-analysis of fasudil injection in treating chronic obstructive pulmonary disease complicated with pulmonary hypertension. Journal of Medical Research, 2012, 44(9):5.

[3]Zhao Yuling, Dong Ya, Fan Yali, et al. Meta-analysis of clinical efficacy of azithromycin combined with simvastatin in the treatment of chronic obstructive pulmonary disease complicated with pulmonary hypertension. Journal of Practical Cardiopulmonary Vascular Diseases, 2018, 26(03):8-12.

[4]Zhang Jing, Cha Zhaoyu, Wang Chunyan. Meta-analysis of simvastatin in treating patients with chronic obstructive pulmonary disease complicated with pulmonary hypertension. Guizhou Medicine, 2016, 40(003):282-284.

[5]Zhang Yuqing, Feng Jing. Systematic evaluation of the therapeutic effect of statins on chronic obstructive pulmonary disease complicated with pulmonary hypertension and its adverse reactions based on gene polymorphism. Chongqing Medical University, 2010.

[6]Ouyang Zhicheng. Systematic evaluation of azithromycin combined with simvastatin in the treatment of chronic obstructive pulmonary disease complicated with pulmonary hypertension. Nanchang University; Medical college of nanchang university, 2017.

[7]Feng Jing. Systematic evaluation of the therapeutic effect of statins on chronic obstructive pulmonary disease complicated with pulmonary hypertension and its adverse reactions based on gene polymorphism. Chongqing Medical University.

[8]Wang Lingling, Shi Hanyu, Dong Yan, Wei Luqing, et al. Meta-analysis of pulmonary fibrosis complicated with emphysema syndrome complicated with pulmonary hypertension. Chinese Journal of Pulmonary Diseases, 2011, 012(003):289-295.

[9]Han Bei. Meta-analysis of efficacy and safety of prostacyclins in the treatment of pulmonary hypertension. Central South University, 2010.

[10]Zheng Jincong, Lin Wangchun, Li Ailin. Systematic evaluation of the efficacy of Fasudil in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. Evaluation and Analysis of Drug Use in China Hospital, 2019(6).

[11]Anonymous. A systematic review of azithromycin combined with simvastatin in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. 2018.

[12]Lue Wang Li, Ma Xun, Tao Jun, et al. Meta-analysis of pulmonary thromboendarterectomy in the treatment of chronic embolic pulmonary hypertension. 2016.

[13]Wang Fahui, Lin Shining, Chen Shan, et al. Analysis of therapeutic value of azithromycin combined with simvastatin on chronic obstructive pulmonary disease complicated with pulmonary hypertension. Proceedings of the 2016 Academic Annual Meeting of China Hospital Pharmacy Journal. 2016.

[14]Wan Jing, Wang Xinhua, Chen Xiaoyan, et al. Meta- analysis of the efficacy and safety of high-dose sildenafil in the treatment of neonatal persistent pulmonary hypertension. Chinese Science and Technology Information Catalogue-Chinese Herbal Medicine, 2020(006):043.

[15]LeeTM, Zhang Ying, Jin Chunyan, liu hongyan, Zhou Hui, Ning Jie. Meta-analysis of therapeutic effect of fasudil on pulmonary hypertension. Modern Medicine and Clinical, 2009.

[16]Cao Yanhong. Cao Yanhong's treatment analysis of chronic obstructive pulmonary disease complicated with pulmonary hypertension, 2012. 

[17]Treatment analysis, Bosentan. Clinical treatment analysis of patients with congenital heart disease complicated with pulmonary hypertension. Ct diagnosis of pneumonia, 2015.

[18]ZHAOKao-chang, Chen Guozhong, Zhao Kao-Chang, et al. Meta-analysis of therapeutic effects of statins on patients with chronic obstructive pulmonary disease. Hainan Medical, 2015, 26(2):5.

[19]He Fang, Liu Meicheng, Qin Qin. Meta-analysis of long-term use of statins to reduce the risk of death and pulmonary artery pressure in COPD patients. Journal of Pharmacoepidemiology, 2018, 27(12):8.

[20]Zheng Jincong, Lin Wangchun, Li Ailin. Systematic evaluation of the efficacy of Fasudil in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. Evaluation and Analysis of Drug Use in China Hospital, 2019, 19(6):5.

[21]Zhen Ling, Li Lu, Liu Jiyang, et al. Systematic review of low-dose azithromycin combined with simvastatin in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. chinese journal of modern applied pharmacy, 2018, 35(1):6.

[22]Cui Xiaojiao. A reticular meta-analysis of the therapeutic effect of statins on COPD with pulmonary hypertension.

[23]Chen Cong, Chen Yuzhen, Li Tao. Meta-analysis of statins combined with sildenafil in the treatment of pulmonary hypertension. Today Pharmacy, 2018, 28(3):7.

[24]Zhao Shanshan, Qin Fang, Li Jing. Meta-analysis of alprostadil in the treatment of patients with chronic pulmonary heart disease and pulmonary hypertension. clinical medication journal, 2019, 17(1):6.

[25]Tang Yanfen Yin Tiping. Analysis of virus infection and biomarkers in patients with acute exacerbation of chronic obstructive pulmonary disease. Wannan Medical College, 2010.

[26]Liu Yang. meta-analysis of clinical efficacy of traditional Chinese medicine in treating COPD complicated with pulmonary hypertension. Liaoning University of Traditional Chinese Medicine, 2018.

[27]Meng Xiaohua. Meta-analysis of short-term efficacy and safety of inhaled nitric oxide in the treatment of children with congenital heart disease complicated with pulmonary hypertension after operation. Guangxi Medical University, 2012.

[28]He Bing. Meta-analysis of randomized controlled trials of drug therapy for pulmonary hypertension. Wuhan University, 2011.

[29]Liu Fang. Meta-analysis of statins in treating pulmonary hypertension. Shandong University, 2011.

[30]Ge Xiaoyan. meta-analysis of the effect of statins on pulmonary function of COPD patients with PH. Road to Health, 2014(4):11-11.

[31]Lue Wang Li, Ma Xun, Tao Jun, et al. Meta-analysis of pulmonary thromboendarterectomy in the treatment of chronic embolic pulmonary hypertension. Electronic Journal of Integrated Chinese and Western Medicine Cardiovascular Disease, 2016, 4(3):4.

[32]XU Ji-chao, Xu Jichao, WEI Qiang-hua, et al. Meta-analysis of risk factors of systemic lupus erythematosus complicated with pulmonary hypertension. 13th World Symposium on Long-term Care in Chinese Regions and Shanghai Gerontology Society Young Scholars Sub-forum. 2016.

[33]Liu Peili, Liu Dongli, Pang Yusheng. Systematic evaluation of short-term efficacy and safety of sildenafil in the treatment of children with congenital heart disease complicated with pulmonary hypertension before or after operation . China Journal of Evidence-based Pediatrics, 2010, 6(5):381-385.

[34]Kuang Tu-guang, Wang Jun, Zhai Zhen-guo, et al. Meta-analysis of efficacy and safety evaluation of bosentan in treating pulmonary hypertension. China Journal of Physician Training: Internal Medicine Edition, 2006(34).

[35]Zhu Peng, Zhang Wei. Meta-analysis of alprostadil lipid microsphere carrier preparation in the treatment of chronic pulmonary heart disease. Journal of Nanchang University: Medical Edition, 2019, 59(4):8.

[36]Wang Wuwan. Meta-analysis of efficacy and safety of targeted drugs for pulmonary hypertension in patients with Fontan circulation . Chongqing Medical University.

[37]Zhou Yanqi. Meta-analysis of efficacy and safety of Celexipa in the treatment of pulmonary hypertension.

[38]Oxford Mu, Guo Xuqiong, Guo Jing, et al. Meta-analysis of therapeutic effect of fasudil on acute exacerbation of COPD with pulmonary hypertension. Shandong Medicine, 2015, 000(034):48-51.

[39]Zhang Ying, Jin Chunyan, liu hongyan, et al. Meta-analysis of therapeutic effect of Fasudil on pulmonary hypertension. Modern Medicine and Clinical, 2015, 30(006):726-731.

[40]Liang Fuxiang, Song Bing, Qi Quan, Meta al. The efficacy and tolerance of endothelin receptor antagonists in the treatment of pulmonary hypertension. China Journal of Evidence-based Cardiovascular Medicine, 2014, 6(6):7.

[41]Xia Jing, Xin Huang, Yang Yanyan. Meta-analysis of efficacy and safety of atorvastatin in the treatment of pulmonary hypertension. strait pharmaceutical journal, 2022(008):034.

[42]Zhou Yanqi, Yu Gengsheng. Meta-analysis of efficacy and safety of Selexipag in the treatment of pulmonary hypertension. Journal of Clinical Cardiovascular Diseases, 2020(3):5.

[43]Yin Dawei, Shi Hanyu, Wei Luqing. Meta-analysis of safety and tolerance of prostacyclin analogues in the treatment of pulmonary hypertension. Armed Police Medicine, 2020(7):5.

[44]Li Min, Wen Fuqiang. Meta-analysis of statins in the treatment of chronic obstructive pulmonary disease with pulmonary hypertension. Western Medicine, 2013, 25(1):5.

[45]Jiang Jiajia, Feng Jing, Dai Rong, et al. Meta-analysis of therapeutic effect of statins on chronic obstructive pulmonary disease complicated with pulmonary hypertension. Medical Herald, 2017, 36(3):12.

[46]Zhao Yuling, Dong Ya, Fan Yali, et al. Meta-analysis of clinical efficacy of azithromycin combined with simvastatin in the treatment of chronic obstructive pulmonary disease complicated with pulmonary hypertension. Journal of Practical Cardiopulmonary Vascular Diseases, 2018, 26(3):5.

[47]Kuang Tu-guang, Wang Jun, Zhai Zhen-guo, et al. Meta-analysis of efficacy and safety evaluation of bosentan in the treatment of pulmonary hypertension. China Journal of Physician's Continuing Education: Internal Medicine Edition, 2006.

[48]Kuang Tu-guang, Wang Jun, Zhai Zhen-guo, et al. Meta-analysis of efficacy and safety evaluation of bosentan in the treatment of pulmonary hypertension. China Journal of Physician's Continuing Education, 2006.

[49]Zhao Honglin, Hui Xu, Lu Zhenxing, et al. Meta-analysis of prostacyclin targeted drugs in the treatment of pulmonary hypertension. China Journal of Evidence-based Medicine, 2018, 18(11):10.

[50]Chen Yuan. meta-analysis of correlation between endothelin receptor antagonist combined with phosphodiesterase inhibitor type 5 in the treatment of RCT in pulmonary hypertension. Nanchang University, 2018.

[51]Dai Zhichu, Zhang Lijun. Meta-analysis of efficacy and safety of Liausi gung in the treatment of pulmonary hypertension. China Pharmaceutical, 2017, 26(8):5.

[52]Zhang Ying, Jin Chunyan, liu hongyan, et al. Meta-analysis of therapeutic effect of Fasudil on pulmonary hypertension. Modern Medicine and Clinical, 2015(6):6.

[53]Oxford Mu, Guo Xuqiong, Guo Jing, et al. Meta-analysis of therapeutic effect of fasudil on acute exacerbation of COPD with pulmonary hypertension. Shandong Medicine, 2015(34):54-57.